Coagulation and the vessel wall in thrombosis and atherosclerosis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 11, 2012, Pages 557-566

  Kleinegris, Marie Claire ^a   Ten Cate Hoek, Arina J ^a   Ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Coagulation; Endothelium; Thrombosis; Vessel wall

Indexed keywords

ACTIVATED PROTEIN C; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; DABIGATRAN; FIBRIN; FIBRINOGEN; HEPARIN COFACTOR II; LIPOPROTEIN A; MELAGATRAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROTEIN C; PROTEIN S; PROTHROMBIN; RIVAROXABAN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DNA POLYMORPHISM; FIBRINOGEN DEFECT; FIBRINOLYSIS; GENE MUTATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; IMMUNITY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ENDOTHELIUM; VEIN BLOOD FLOW; VEIN THROMBOSIS;

EID: 84872353494     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1464     Document Type: Review

References (77)

1. Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Clin Epidemiol. 2009; 1: 1-6.
2. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005; 26: 3-4.
3. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001; 134: 224-238.
4. Lip GY, Blann AD. Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state? J Am Coll Cardiol. 2000; 36: 2044-2046.
5. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997; 277: 642-645.
6. Vayá A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Hematol. 2002; 118: 255-259.
7. Prandoni P, Piovella C, Pesavento R. Venous thromboembolism and arterial complications. Semin Respir Crit Care Med. 2012; 33: 205-210.
8. Lijfering WM, Flinterman LE, Vandenbroucke JP, et al. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011; 37: 885-896.
9. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006; 4: 1891-1896.
10. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; 364: 1746-1760.
11. Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006; 103: 3106-3111.
12. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993; 92: 1207-1212.
13. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000; 89: 160-167.
14. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Ann Rev Med. 1996; 47: 315-331.
15. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012; 2: a006 429.
16. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997; 77: 408-423.
17. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med. 1995; 5: 141-148.
18. Ishii H, Salem HH, Bell CE, et al. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood. 1986; 67: 362-365.
19. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989; 264: 10396-10401.
20. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res. 1989; 53: 231-241.
21. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340: 1555-1564.
22. Randolph GJ, Luther T, Albrecht S, et al. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood. 1998; 92: 4167-4177.
23. Thiruvikraman SV, Guha A, Roboz J, et al. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Ivest. 1996; 75: 451-461.
24. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res. 2009; 82: 392-403.
25. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993; 22: 609-616.
26. Mizuno O, Hirano K, Nishimura J, et al. Mechanism of endothelium- dependent relaxation induced by thrombin in the pig coronary artery. Eur J Pharmacol. 1998; 351: 67-77.
27. Hamilton JR, Cocks TM. Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery. Br J Pharmacol. 2000; 130: 181-188.
28. Gudmundsdóttir IJ, Lang NN, Boon NA, et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol. 2008; 51: 1749-1756.
29. Yang L, Lewis CM, Chandrasekharan UM, et al. Arginase activity is increased by thrombin: a mechanism for endothelial dysfunction in arterial thrombosis. J Am Coll Surg. 2006; 203: 817-826.
30. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999; 85: 394-402.
31. Zhang C, Hein TW, Wang W, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension. 2004; 44: 935-943.
32. Rabiet MJ, Plantier JL, Rival Y, et al. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol. 1996; 16: 488-496.
33. Vuong PT, Malik AB, Nagpala PG, Lum H. Protein kinase C beta modulates thrombin-induced Ca2+ signaling and endothelial permeability increase. J Cell Physiol. 1998; 175: 379-387.
34. Schulz B, Pruessmeyer J, Maretzky T, et al. ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res. 2008; 102: 1192-1201.
35. Laszik ZG, Zhou XJ, Ferrell GL, et al. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol. 2001; 159: 797-802.
36. Mari D, Mannucci PM, Coppola R, et al. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995; 85: 3144-3149.
37. Minami T, Sugiyama A, Wu SQ, et al. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004; 24: 41-53.
38. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol. 1997; 158: 5435-541.
39. Sugama Y, Malik AB. Thrombin receptor 14-amino acid peptide mediates endothelial hyperadhesivity and neutrophil adhesion by P-selectin-dependent mechanism. Circ Res. 1992; 71: 1015-109.
40. Ostrovsky L, Carvalho-Tavares J, Woodman RC, Kubes P. Translational inhibition of E-selectin expression stimulates P-selectin-dependent neutrophil recruitment. Am J Physiol Heart Circ Physiol. 2000; 278: H1225-H1232.
41. Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012; 10: 1207-1216.
42. Kadoglou NP, Moustardas P, Katsimpoulas M, et al. The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice: Dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther. 2012; 26: 367-374.
43. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26: 2787-2792.
44. Castellino FJ, Ganopolsky JG, Noria F, et al. Focal arterial inflammation is augmented in mice with a deficiency of the protein C gene. Thromb Haemost. 2006; 96: 794-801.
45. Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001; 103: 3044-3046.
46. Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation. 2009; 120: 774-784.
47. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997; 89: 2817-2821.
48. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20 210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997; 90: 1747-1750.
49. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003; 107: 1117-1122.
50. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367: 651-658.
51. Weischer M, Juul K, Zacho J, et al. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis. 2010; 208: 480-483.
52. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012; 32: 563-568.
53. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009; 7 Suppl 1: 301-304.
54. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000; 95: 1117-1123.
55. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91: 2850-2860.
56. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000; 95: 1680-1686.
57. Ely EW, Laterre PF, Angus DC, et al.; PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003; 31: 12-19.
58. Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev. 2012; 3: CD004 388.
59. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010. 376: 1498-509.
60. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Hematol. 2007; 137: 181-192.
61. Sozer S, Fiel MI, Schiano T, et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009; 113: 5246-5249.
62. Marchetti M, Vignoli A, Bani MR, et al. All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica. 2003; 88: 895-905.
63. Zhu J, Xie R, Piao X, et al. Homocysteine enhances clot-promoting activity of endothelial cells via phosphatidylserine externalization and microparticles formation. Amino Acids. 2012; 43: 1243-1250.
64. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest. 2012; 42: 1126-1135.
65. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003; 348: 1435-1441.
66. Hong C, Zhu F, Du D, et al. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis. 2005; 183: 169-174.
67. Eliasson A, Bergqvist D, Björck M, et al. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecuti ve autopsies. J Thromb Haemost. 2006; 4: 1897-1902.
68. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008; 117: 93-102.
69. Chatrou ML, Winckers K, Hackeng TM, et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012; 26: 155-166.
70. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 386: 78-81.
71. Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation. 2001; 103: 1051-1056.
72. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004; 104: 3231-3232.
73. Koos R, Mahnken AH, Mühlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005; 96: 747-749.
74. Lerner RG, Aronow WS, Sekhri A, et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost. 2009; 7: 2023-2207.
75. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011; 32: 2555-2562.
76. Lee IO, Kratz MT, Schirmer SH, et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein e-deficient mice. J Pharmacol Exp Ther. 2012; 343: 253-257.
77. Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011; 2011: 432080